A review on the efficacy and safety of gabapentin in the treatment of chronic cough

Ryan, Nicole

doi:10.1517/14656566.2015.981524

Cited by 26 publications

(22 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The magnitude of change in LCQ and cough severity in the pregabalin study was greater than the gabapentin study; however, adverse effects were higher. Pregabalin has greater abuse potential compared to gabapentin most likely due to its more rapid absorption and faster onset of action [103]. …”

Section: Resultsmentioning

confidence: 99%

An update and systematic review on drug therapies for the treatment of refractory chronic cough

Ryan

Vertigan

Birring

2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: Chronic Cough (CC) is common and often associated with significant comorbidity and decreased quality of life. In up to 50% of cases, the cough is refractory despite extensive investigation and treatment trials. It is likely that the key abnormality in refractory CC is dysfunctional, hypersensitive sensory nerves, similar to conditions such as laryngeal hypersensitivity and neuropathic pain.Areas covered: The aim of this systematic review is to assess drug therapies for refractory CC. The authors review the current management of CC and provide discussion of the similarities between neuropathic pain and refractory CC. They review repurposed and new pharmacological treatments. Several meta-analyses were performed to compare the efficacy of treatments where possible.Expert opinion: Repurposed pain medications such as gabapentin and pregabalin reduce the frequency of cough and improve quality of life. Along with speech pathology, they are important and alternate treatments for refractory CC. However, more treatments are needed and the P2X3 ion channel receptor antagonists show the most promise. With a better understanding of neuronal activation and sensitisation and their signal processing in the brain, improved animal models of cough, and the use of validated cough measurement tools, more effective treatments will develop.

show abstract

Section: Resultsmentioning

confidence: 99%

An update and systematic review on drug therapies for the treatment of refractory chronic cough

Ryan

Vertigan

Birring

2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Therefore, to restore normal cough sensitivity and inhibit pathological cough under the premise of preserving the protective effect of cough re ex are an ideal therapeutic strategy. The rationale for gabapentin treating CRC is the similar central hypersensitivity of chronic cough to neuropathic pain and the proven e cacious effectiveness of gabapentin in chronic pain [22][23][24][25] . Our study has supported that gabapentin is an effective regimen for CRC, as indicated by a favorable response to gabapentin in the majority of recruited patients.…”

Section: Discussionmentioning

confidence: 99%

Prediction of Therapeutic Efficacy of Gabapentin by Hull Airway Reflux Questionnaire in Chronic Refractory Cough

Zhang

Chen

Dong

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundGabapentin is recommended for the treatment of chronic refractory cough. This study aims to identify its therapeutic predictors in a prospective clinical study.Methods179 patients with chronic refractory cough were treated with gabapentin. Prior to the therapy, all patients were assessed by Hull Airway Reflux Questionnaire (HARQ) and inhaled capsaicin test. When the treatment ended and cough resolution was confirmed, a stepwise logistic regression analysis was performed to identify the therapeutic predictors for gabapentin and to establish the prediction equation. ResultsGabapentin treatment achieved a therapeutic success rate of 66.5%. HARQ scores were significantly higher in responders than non-responders to gabapentin (29.79 ± 9.58 vs 21.95 ± 7.83, t = -3.685, P = 0.000), which were positively related to the therapeutic efficacy of gabapentin (r = 0.433, P < 0.01). The optimal cutoff point of 21.5 in HARQ presented with a moderate ability to predict gabapentin efficacy, with a sensitivity of 84.6% and specificity of 63.6%. Multiple logistic regression identified items of “A tickle in your throat, or a lump in your throat” (OR= 7.927, P=0.005), “Cough when you get out of bed in the morning” (OR=7.016, P=0.045) and “Cough with eating” (OR=6.689, P=0.011) as independent predictors. The established logistic regression equation predicted ³ 80% of the treatment success rate of gabapentin, which was verified by consequent preliminary revalidating study in 59 patients.ConclusionsHARQ may be useful to screen patients with chronic refractory cough most likely responsive to gabapentin, and help improve the therapeutic success. Trial registrationhttp://www.chictr.org/; No.: ChiCTR-ONC-13003123

show abstract

“…Gabapentin: several case series and reports have described the use of gabapentin in chronic cough 48. A randomised controlled trial (n=62) found that gabapentin used for 10 weeks (up to a maximum dose of 1800 mg/day) resulted in a small improvement in LCQ score compared with placebo 49.…”

Section: Further Specialist Managementmentioning

confidence: 99%

Chronic cough: a practical approach to assessment and management

Mathur

Munro²,

Currie³

2019

DTB

View full text Add to dashboard Cite

A review on the efficacy and safety of gabapentin in the treatment of chronic cough

Cited by 26 publications

References 65 publications

An update and systematic review on drug therapies for the treatment of refractory chronic cough

An update and systematic review on drug therapies for the treatment of refractory chronic cough

Prediction of Therapeutic Efficacy of Gabapentin by Hull Airway Reflux Questionnaire in Chronic Refractory Cough

Chronic cough: a practical approach to assessment and management

Contact Info

Product

Resources

About